PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2026

While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, GlobalData expects this market to undergo substantial growth between 2016 and 2026, doubling over the forecast period. The main driver of this enormous expansion will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle. The second largest driver will be physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Despite the large number of marketed therapies, the T2D market is still experiencing large unmet needs and therefore has a significant growth opportunity for new patent-protected products. Metformin (dimethylbiguanide) will remain the first-line therapy overall for T2D due to physicians’ familiarity with it and the availability of long-term data, but the usage of sulfonylureas (SUs), another front-line therapy, continues to be replaced by novel therapies with improved side-effect profiles. The battle for second- or third-line therapy will involve DPP-4Is, GLP-1RAs, SGLT-Is, and other upcoming novel therapies. Of all the currently marketed classes, GLP-1RAs and SGLT-Is will experience the fastest growth due to their beneficial CV effects, weight-loss effects, and increasing ease of use.

Scope

Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global T2D therapeutics market from 2016-2026.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Adocia

Astellas Pharma

AstraZeneca

Biocon

Boehringer Ingelheim

Bristol-Myers Squibb

Chong Kun Dang

Chugai Pharmaceuticals

Daiichi Sankyo

Diasome

Eli Lilly

GlaxoSmithKline

Intarcia Therapeutics

Ionis Pharmaceuticals

Johnson ...

Adocia

Astellas Pharma

AstraZeneca

Biocon

Boehringer Ingelheim

Bristol-Myers Squibb

Chong Kun Dang

Chugai Pharmaceuticals

Daiichi Sankyo

Diasome

Eli Lilly

GlaxoSmithKline

Intarcia Therapeutics

Ionis Pharmaceuticals

Johnson & Johnson

Kowa Company

LG Life Sciences

Ligand Pharmaceuticals

Merck & Co

Mitsubishi Tanabe

Novartis

Novo Nordisk

OPKO Health

Pfizer

Poxel SA

Roche

Sanofi

SatRx

Shenzhen Chipscreen Biosciences

Taisho Pharmaceuticals

Takeda

Theracos

vTv Therapeutics Inc

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Type 2 Diabetes (T2D): Executive Summary

2 ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Type 2 Diabetes (T2D): Executive Summary

2.1 T2D Sales to Double Across 7MM

2.2 Multiple Opportunities Exist to Address Existing T2D Market Unmet Needs

2.3 The Arrival of Insulin Biosimilars and Abundance of “Me-Too” Drugs Illustrates Corporate Shift in Focus from Therapeutic Value Towards Competitive Pricing and Non-novel Agents that Confer Incremental Benefits

2.4 Glucagon-Like Peptide -1 Receptor Agonist Class Faces Intense Internal Competition, Largely Revolving Around Drugs’ Ability to Improve Patient Compliance/Ease of Administration and Cardiovascular Effects

2.5 Newest T2D Drug Class, Sodium-Glucose Cotransporter Inhibitors, Will Continue To Gain Significant Market Share Despite Concerns

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology

4.2 Pathophysiology

4.3 Symptoms

4.4 Prognosis

4.5 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for T2D in the 8MM (2016–2026)

5.5.1 Diagnosed Prevalent Cases of T2D

5.5.2 Age-Specific Diagnosed Prevalent Cases of T2D

5.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D

5.5.4 Comorbidities Among the Diagnosed Prevalent Cases of T2D

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Diagnosis and Referrals

6.1.2 Treatment Guidelines and Leading Prescribed Drugs

6.1.3 Clinical Practice

6.2 US

6.3 France

6.4 Germany

6.5 Italy

6.6 Spain

6.7 UK

6.8 Japan

7 Competitive Assessment

7.1 Overview

7.2 Strategic Competitor Assessment

7.3 Product Profiles – Major Brands

7.3.1 Metformin

7.3.2 Sulfonylureas and Other Insulin Secretagogues

7.3.3 α-glucosidase Inhibitors

7.3.4 Thiazolidinediones

7.3.5 Glucagon-Like Peptide-1 Receptor Agonists

7.3.6 Dipeptidyl-Peptidase 4 Inhibitors

7.3.7 Sodium-Glucose Cotransporter 2 Inhibitors

7.3.8 Insulin Formulations

8 Unmet Needs and Opportunities

8.1 Overview

8.2 Disease-Modifying Treatments Providing Sustained Glycemic Control

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Drugs with Non-Glycemic Benefits

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Drugs with Improved Side-Effect Profiles

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Increased Patient Compliance

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Trial Mapping

9.2.1 Clinical Trials by Country

9.2.2 Clinical Trials by Phase and Trial Status

9.3 Promising Drugs in Clinical Development

9.3.1 Semaglutide

9.3.2 OG217SC/Semaglutide (oral)

9.3.3 ITCA 650

9.3.4 Ertugliflozin

9.3.5 Sotagliflozin

9.3.6 Bexagliflozin

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 Eli Lilly

10.3.2 Novo Nordisk

10.3.3 Sanofi

10.3.4 AstraZeneca

10.3.5 Merck & Co.

10.3.6 Boehringer Ingelheim

10.3.7 GlaxoSmithKline

10.3.8 Takeda

10.3.9 Roche

10.3.10 Pfizer

10.3.11 Johnson & Johnson

10.3.12 Novartis

10.3.13 Intarcia Therapeutics

10.3.14 Theracos

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 France

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Germany

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 Italy

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

11.6 Spain

11.6.1 Forecast

11.6.2 Key Events

11.6.3 Drivers and Barriers

11.7 UK

11.7.1 Forecast

11.7.2 Key Events

11.7.3 Drivers and Barriers

11.8 Japan

11.8.1 Forecast

11.8.2 Key Events

11.8.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.4 Forecasting Methodology

12.4.1 Diagnosed T2D Patients

12.4.2 Percent Drug-Treated Patients

12.4.3 Drugs Included in Each Therapeutic Class

12.4.4 Launch and Patent Expiry Dates

12.4.5 General Pricing Assumptions

12.4.6 Individual Drug Assumptions

12.4.7 Generic Erosion

12.4.8 Pricing of Pipeline Agents

12.5 Physicians and Specialists Included in this Study

12.6 About the Authors

12.6.1 Managing Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologists

12.6.4 Global Director of Therapy Analysis and Epidemiology

12.6.5 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of tables

Table 1: T2D: Key Metrics in the Seven Major Pharmaceutical Markets

Table 2: Overall Unmet Needs – Current Level of Attainment

Table 3: Primary pathophysiologic conditions ...

Table 1: T2D: Key Metrics in the Seven Major Pharmaceutical Markets

Table 2: Overall Unmet Needs – Current Level of Attainment

Table 3: Primary pathophysiologic conditions associated with T2D

Table 4: Symptoms of T2D

Table 5: Risk Factors and Comorbidities for T2D.

Table 6: 7MM, Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, Selected Years 2016–2026

Table 7: Diagnostic Tests and Typical Criteria for Diagnosing T2D

Table 8: T2D Treatments

Table 9: Country Profile, T2D Management, US

Table 10: Country Profile, T2D Management, France

Table 11: Country Profile, T2D Management, Germany

Table 12: Country Profile, T2D Management, Italy

Table 13: Country Profile, T2D Management, Spain

Table 14: Country Profile, T2D Management, UK

Table 15: Country Profile, T2D Management, Japan

Table 16: Leading Branded Treatments for T2D, 2016

Table 17: Product Profile – Metformin

Table 18: Metformin SWOT Analysis, 2016

Table 19: First-Generation SUs

Table 20: Second-Generation SUs

Table 21: : Product Profile – SUsTable 26

Table 22: SUs SWOT Analysis, 2016

Table 23: Product Profile – Acarbose

Table 24: AGIs SWOT Analysis, 2016

Table 25: Product Profile – Actos

Table 26: TZDs SWOT Analysis, 2016

Table 27: GLP-1RAs

Table 28: Product Profile – Byetta

Table 29: Byetta SWOT Analysis, 2016

Table 30: Product Profile – Victoza

Table 31: Victoza SWOT Analysis, 2016

Table 32: Product Profile – Bydureon

Table 33: Bydureon SWOT Analysis, 2016

Table 34: Product Profile – Lyxumia

Table 35: Lyxumia SWOT Analysis, 2016

Table 36: Product Profile – Tanzeum

Table 37: Tanzeum SWOT Analysis, 2016

Table 38: Product Profile – Trulicity

Table 39: Trulicity SWOT Analysis, 2016

Table 40: Marketed DPP-4Is

Table 41: Marketed DPP-4Is in Combination with Other OADs

Table 42: Product Profile – Januvia

Table 43: Januvia SWOT Analysis, 2016

Table 44: Product Profile – Onglyza

Table 45: Onglyza SWOT Analysis, 2016

Table 46: Product Profile – Tradjenta

Table 47: Tradjenta SWOT Analysis, 2016

Table 48: Product Profile – Galvus

Table 49: Galvus SWOT Analysis, 2016

Table 50: Product Profile – Nesina

Table 51: Nesina SWOT Analysis, 2016

Table 52: Product Profile – Tenelia

Table 53: Tenelia SWOT Analysis, 2016

Table 54: Product Profile – Suiny

Table 55: Suiny SWOT Analysis, 2016

Table 56: Product Profile – Zafatek

Table 57: Zafatek SWOT Analysis, 2016

Table 58: Product Profile – Marizev

Table 59: Marizev SWOT Analysis, 2016

Table 60: SGLT-2Is

Table 61: Marketed SGLT-2Is in Combination with Other T2D Drugs

Table 62: Product Profile – Forxiga

Table 63: Forxiga SWOT Analysis, 2016

Table 64: Product Profile – Invokana

Table 65: Invokana SWOT Analysis, 2016

Table 66: Product Profile – Jardiance

Table 67: Jardiance SWOT Analysis, 2016

Table 68: Product Profile – Apleway

Table 69: Apleway SWOT Analysis, 2016

Table 70: Product Profile – Suglat

Table 71: Suglat SWOT Analysis, 2016

Table 72: Product Profile – Lusefi

Table 73: Lusefi SWOT Analysis, 2016

Table 74: Insulins – Overview and Comparison

Table 75: Marketed Combination Insulins

Table 76: Insulin Formulations

Table 77: Product Profile – Humalog

Table 78: Humalog SWOT Analysis, 2016

Table 79: Product Profile – Lantus

Table 80: Lantus SWOT Analysis, 2016

Table 81: Toujeo SWOT Analysis, 2016

Table 82: Product Profile – Levemir

Table 83: Levemir SWOT Analysis, 2016

Table 84: Product Profile – NovoLog

Table 85: NovoLog SWOT Analysis, 2016

Table 86: Fiasp SWOT Analysis, 2016

Table 87: Product Profile – Apidra

Table 88: Apidra SWOT Analysis, 2016

Table 89: Product Profile – Tresiba

Table 90: Tresiba SWOT Analysis, 2016

Table 91: Product Profile – Afrezza

Table 92: Afrezza SWOT Analysis, 2016

Table 93: Product Profile – Insulin glargine biosimilars

Table 94: Insulin Glargine Biosimilars SWOT Analysis, 2016

Table 95: Unmet Needs and Opportunities in T2D

Table 96: T2D – Clinical Trials by Phase and Status, 2016

Table 97: T2D – Phase Pipeline, 2016

Table 98: Comparison of Therapeutic Classes in Development for T2D, 2016

Table 99: Product Profile – Semaglutide

Table 100: Semaglutide SWOT Analysis, 2016

Table 101: Product Profile – OG217SC

Table 102: OG217SC SWOT Analysis, 2016

Table 103: Product Profile – ITCA 650

Table 104: ITCA 650 SWOT Analysis, 2016

Table 105: Product Profile – Ertugliflozin

Table 106: Ertugliflozin SWOT Analysis, 2016

Table 107: Product Profile – Sotagliflozin

Table 108: Sotagliflozin SWOT Analysis, 2016

Table 109: Product Profile – Bexagliflozin

Table 110: Bexagliflozin SWOT Analysis, 2016

Table 111: Key Companies in the T2D Market, 2016

Table 112: Other Companies in the T2D Market, 2016

Table 113: Eli Lilly’s T2D Portfolio Assessment, 2016

Table 114: Eli Lilly SWOT Analysis, 2016

Table 115: Novo Nordisk’s T2D Portfolio Assessment, 2016

Table 116: Novo Nordisk SWOT Analysis, 2016

Table 117: Sanofi’s T2D Portfolio Assessment, 2016

Table 118: Sanofi SWOT Analysis, 2016

Table 119: AstraZeneca’s T2D Portfolio Assessment, 2016

Table 120: AstraZeneca SWOT Analysis, 2016

Table 121: Merck’s T2D Portfolio Assessment, 2016

Table 122: Merck SWOT Analysis, 2016

Table 123: BI’s T2D Portfolio Assessment, 2016

Table 124: BI SWOT Analysis, 2016

Table 125: GSK’s T2D Portfolio Assessment, 2016

Table 126: GSK SWOT Analysis, 2016

Table 127: Takeda’s T2D Portfolio Assessment, 2016

Table 128: Takeda SWOT Analysis, 2016

Table 129: Roche’s T2D Portfolio Assessment, 2016

Table 130: Roche SWOT Analysis, 2016

Table 131: Pfizer’s T2D Portfolio Assessment, 2016

Table 132: Pfizer SWOT Analysis, 2016

Table 133: J&J’s T2D Portfolio Assessment, 2016

Table 134: J&J SWOT Analysis, 2016

Table 135: Novartis’ T2D Portfolio Assessment, 2016

Table 136: Novartis SWOT Analysis, 2016

Table 137: Intarcia Therapeutics’ T2D Portfolio Assessment, 2016

Table 138: Intarcia Therapeutics SWOT Analysis, 2016

Table 139: Theracos’ T2D Portfolio Assessment, 2016

Table 140: Theracos, SWOT Analysis, 2016

Table 141: T2D Market – Drivers and Barriers, 2016

Table 142: Key Events Impacting Sales for T2D in US, 2016–2026

Table 143: T2D Market – Drivers and Barriers in the US, 2016

Table 144: Key Events Impacting Sales for T2D in Germany, 2016–2026

Table 145: T2D Market – Drivers and Barriers in France, 2016

Table 146: Key Events Impacting Sales for T2D in Germany, 2016–2026

Table 147: T2D Market – Drivers and Barriers in Germany, 2016

Table 148: Key Events Impacting Sales for T2D in Italy, 2016–2026

Table 149: T2D Market – Drivers and Barriers in Italy, 2016

Table 150: Key Events Impacting Sales for T2D in Spain, 2016–2026

Table 151: T2D Market – Drivers and Barriers in Spain, 2016

Table 152: Key Events Impacting Sales for T2D in the UK, 2016–2026

Table 153: T2D Market – Drivers and Barriers in the UK, 2016

Table 154: Key Events Impacting Sales for T2D in Japan, 2016–2026

Table 155: T2D Market – Drivers and Barriers in Japan, 2016

Table 156: Key Launch Dates

Table 157: Key Patent Expiries

Table 158: Number of High-Prescribing Physicians Surveyed

List of figures

Figure 1: Global Sales for T2D by Country/Region, 2016 and 2026

Figure 2: Company Portfolio Gap Analysis in T2D, 2016–2026

Figure 3: Competitive ...

Figure 1: Global Sales for T2D by Country/Region, 2016 and 2026

Figure 2: Company Portfolio Gap Analysis in T2D, 2016–2026

Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in T2D, 2016–2026

Figure 4: T2D Pathophysiology

Figure 5: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D , Men, Ages ≥20 Years, 2006–2026

Figure 6: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D , Women, Ages ≥20 Years, 2006–2026

Figure 7: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of T2D

Figure 8: 7MM, Sources Used, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D

Figure 9: 7MM, Sources Used, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D

Figure 10: 7MM, Sources Used, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D

Figure 11: 7MM, Sources Used, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D

Figure 12: 7MM, Sources Used, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D

Figure 13: 7MM, Age-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016

Figure 14: 7MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N, 2016

Figure 15: 7MM, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016

Figure 16: 7MM, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016

Figure 17: 7MM, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016

Figure 18: 7MM, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016

Figure 19: 7MM, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016

Figure 20: Incretin and SGLT-2I Mechanisms of Action

Figure 21: ADA/EASD General Recommendations for Antihyperglycemic Therapy

Figure 22: Pipeline Agents in Develpoment for T2D

Figure 23: Competitive Assessment of Late-Stage Pipeline Agents in T2D, 2016–2026

Figure 24: Company Portfolio Gap Analysis in T2D, 2016–2026

Figure 25: Global Sales for T2D by Country/Region, 2016 and 2026

Figure 26: Sales for T2D in the US by Drug Class, 2016 and 2026

Figure 27: Sales for T2D in the France by Drug Class, 2016 and 2026

Figure 28: Sales for T2D in the Germany by Drug Class, 2016 and 2026

Figure 29: Sales for T2D in the Italy by Drug Class, 2016 and 2026

Figure 30: Sales for T2D in the Spain by Drug Class, 2016 and 2026

Figure 31: Sales for T2D in the UK by Drug Class, 2016 and 2026

Figure 32: Sales for T2D in the Japan by Drug Class, 2016 and 2026

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports